Citi analyst Daniel Grosslight is opening a "Catalyst Watch" on GoodRx as he thinks there is upside to consensus numbers given the intensifying flu, RSV, and COVID season this winter. The analyst, who thinks GoodRx is likely to beat expectations in Q4 of FY22 and Q1 of FY23, has a Buy rating and $7 price target on the shares.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GDRX: